A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 5, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2029

Conditions

Myelodysplastic Syndrome(MDS)Acute Myelogenous Leukemia (AML)

Interventions

DRUG

Nadunolimab

Give by IV

DRUG

Azacitidine

Given by IV

DRUG

Venetoclax

Given by mouth (PO

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER